SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-008502
Filing Date
2023-05-08
Accepted
2023-05-08 16:01:41
Documents
87
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ymab-20230331x10q.htm   iXBRL 10-Q 1893715
2 EX-31.1 ymab-20230331xex31d1.htm EX-31.1 15652
3 EX-31.2 ymab-20230331xex31d2.htm EX-31.2 15545
4 EX-32.1 ymab-20230331xex32d1.htm EX-32.1 7835
5 EX-32.2 ymab-20230331xex32d2.htm EX-32.2 7714
  Complete submission text file 0001558370-23-008502.txt   7732434

Data Files

Seq Description Document Type Size
6 EX-101.SCH ymab-20230331.xsd EX-101.SCH 68148
7 EX-101.CAL ymab-20230331_cal.xml EX-101.CAL 45520
8 EX-101.DEF ymab-20230331_def.xml EX-101.DEF 264028
9 EX-101.LAB ymab-20230331_lab.xml EX-101.LAB 513995
10 EX-101.PRE ymab-20230331_pre.xml EX-101.PRE 444211
81 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20230331x10q_htm.xml XML 1136460
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38650 | Film No.: 23897587
SIC: 2834 Pharmaceutical Preparations